Bivalirudin CAS 128270-60-0 is an anticoagulant For Lab Research

Bivalirudin CAS 128270-60-0 is an anticoagulant For Lab Research

Product Name: Bivalirudin
Synonyms: Bivalirudin, TFA;BIVALIRUDIN;BIVALIRUDIN TRIFLUOROACETATE;BITTERMELONP.E;Human Bivalirudin;DPHE-PRO-ARG-PRO-GLY-GLY-GLY-GLY-ASN-GLY-ASP-PHE-GLU-GLU-LLE-PRO-GLU-GLU-TYR-LEU;Bivalirudin Acetate;Bivalirudin BG 8967, Hirulog, Hirulog I
CAS: 128270-60-0
MF: C98H138N24O33
MW: 2180.29
EINECS: 274-570-6
Product Categories: API;proteins;Peptide
Mol File: 128270-60-0.mol

Bivalirudin is a kind of synthetic novel anticoagulants. It is the direct, specific and reversible inhibitor of thrombin. It was developed by the Swiss Basset (Biogen) originally. Then it was transferred to the United States Medicines Company, and approved for marketing in the United States in 2000. Its anticoagulant ingredient is a kind of 20 peptides derived from hirudin. Bivalirudin can specifically bind with catalytic site and the anion binding site of whether thrombin that is in the blood circulation or thrombus-bound thrombin, thus directly inhibiting thrombin activity. And its role is characterized by short, reversible. Early clinical studies show that the anticoagulation treatment of bivalirudin is good. And the incidence of bleeding events is low. So its use is safer than traditional heparin therapy. It is mainly used for the prevention of angioplasty interventional treatment of ischemic complications of unstable angina pectoris before and after.

Bivalirudin CAS 128270-60-0 Chemical Properties
density 1.52±0.1 g/cm3(Predicted)
storage temp. -20°C
form powder
color white to off-white
InChIKey OIRCOABEOLEUMC-GEJPAHFPSA-N

Uses of Bivalirudin CAS 128270-60-0
Anticoagulant; antithrombotic.

Biluvudine is a synthetic anticoagulant drug, a 20-peptide analogue of hirudin, which was approved for marketing in the United States in 2000. Bivalirudin binds specifically to the catalytic site of thrombin and the anionic external binding site, directly inhibiting the activity of thrombin and thereby inhibiting the reactions catalyzed and induced by thrombin, and its action is reversible. Bivalirudin is mainly used as an anticoagulant for elective percutaneous coronary intervention (PCI) in adults.